scholarly journals Single Cell Whole Exome Sequencing in NPM1/Flt3 Positive Pediatric Acute Myeloid Leukemia

Blood ◽  
2014 ◽  
Vol 124 (21) ◽  
pp. 1043-1043
Author(s):  
Christiane Walter ◽  
Winfried Hofmann ◽  
Katarina Reinhardt ◽  
Dirk Reinhardt ◽  
Nils von Neuhoff

Abstract Introduction: Acute myeloid leukemia (AML) is one of the most frequent forms of leukemia in children younger than 15 years. The detection of several mutations in a blast population of pediatric AML (pAML) is supposed to be caused by a clonal evolution from a leukemic stem cell (LSC) to leukemic blasts. LSC are believed to be more resistant to chemotherapy, to be able to survive during treatment and to be responsible for the emergence of a relapse due to the persistence in the bone marrow (BM) niche. Since LSC and potential leukemic subclones are only present in small subpopulations, it has been a major technical challenge to particular analyse only the specific population. To acquire a better understanding of the underlying mechanisms of mutagenesis, clonal evolution and leukemogenesis, the aim of this study was to establish methods that allow the analysis and detection of mutations in single cells of a subpopulation known to contain HSC as well as LSC (CD34+CD38-). We especially focused on a pAML subgroup with mutations in Nucleophosmin (NPM1) and/or fms related tyrosine kinase 3 (Flt3). Methods and Results: We established methods to perform single cell sorting, whole genome amplification (WGA) using multiple displacement amplification (MDA) technology (Qiagen) and subsequent whole exome sequencing. The sorting efficiency was checked as Hoechst stained cells were sorted onto glas slides with 48 defined spots and the presence of single cells was checked under an inverse fluorescent microscope. Subsequently, single CD34+CD38- patient derived cells were sorted into 0,5ml low binding tubes containing 4µl PBS followed by WGA and whole exome sequencing. The mutational status of the sorted single cells from three patients suffering from pAML was analysed and compared to mutations detected at initial diagnosis in DNA from a bulk of BM cells. WGA from single CD34+CD38-PI- cells resulted in an amount of 29 to 31.7µg DNA from each of five single cells. The quality of the amplified DNA was sufficient for whole exome sequencing. A 4bp insertion in exon 12 of NPM1 reflecting a common NPM1 mutation (MutA) initially detected from a bulk of cells was identified in amplified DNA from single cells using whole exome sequencing in 2/3 patients. Internal tandem duplications in Flt3 indicated by mismatches in the alignment could be detected in amplified DNA from single cells of two patients. The detected ITD resemble those initially detected in DNA from a bulk of BM cells. Discussion and Conclusion: Single cell sequencing provides a useful tool to amend the detection of genetic aberrations from a bulk of cells and to confirm the presence of specific mutations in single cells from small subpopulations. It therefore helps to get further insights into the clonal evolution in pAML. Disclosures No relevant conflicts of interest to declare.

Oncotarget ◽  
2016 ◽  
Vol 7 (35) ◽  
pp. 56746-56757 ◽  
Author(s):  
Riccardo Masetti ◽  
Ilaria Castelli ◽  
Annalisa Astolfi ◽  
Salvatore Nicola Bertuccio ◽  
Valentina Indio ◽  
...  

2020 ◽  
Vol 61 (9) ◽  
pp. 2168-2179
Author(s):  
Louise Pettersson ◽  
Yilun Chen ◽  
Anthony M. George ◽  
Robert Rigo ◽  
Vladimir Lazarevic ◽  
...  

Author(s):  
Kunnathur Murugesan Sakthivel ◽  
Narayanan Geetha ◽  
Thampirajan Vimaladevi Akhila Raj ◽  
Ramachandran Krishna Chandran ◽  
Kumarapillai Mohanan Nair Jagathnath Krishna ◽  
...  

Leukemia ◽  
2013 ◽  
Vol 28 (5) ◽  
pp. 1148-1151 ◽  
Author(s):  
A Pellagatti ◽  
M Fernandez-Mercado ◽  
C Di Genua ◽  
M J Larrayoz ◽  
S Killick ◽  
...  

Blood ◽  
2011 ◽  
Vol 118 (23) ◽  
pp. 6153-6163 ◽  
Author(s):  
Vera Grossmann ◽  
Enrico Tiacci ◽  
Antony B. Holmes ◽  
Alexander Kohlmann ◽  
Maria Paola Martelli ◽  
...  

Abstract Among acute myeloid leukemia (AML) patients with a normal karyotype (CN-AML), NPM1 and CEBPA mutations define World Health Organization 2008 provisional entities accounting for approximately 60% of patients, but the remaining 40% are molecularly poorly characterized. Using whole-exome sequencing of one CN-AML patient lacking mutations in NPM1, CEBPA, FLT3-ITD, IDH1, and MLL-PTD, we newly identified a clonal somatic mutation in BCOR (BCL6 corepressor), a gene located on chromosome Xp11.4. Further analyses of 553 AML patients showed that BCOR mutations occurred in 3.8% of unselected CN-AML patients and represented a substantial fraction (17.1%) of CN-AML patients showing the same genotype as the AML index patient subjected to whole-exome sequencing. BCOR somatic mutations were: (1) disruptive events similar to the germline BCOR mutations causing the oculo-facio-cardio-dental genetic syndrome; (2) associated with decreased BCOR mRNA levels, absence of full-length BCOR, and absent or low expression of a truncated BCOR protein; (3) virtually mutually exclusive with NPM1 mutations; and (4) frequently associated with DNMT3A mutations, suggesting cooperativity among these genetic alterations. Finally, BCOR mutations tended to be associated with an inferior outcome in a cohort of 422 CN-AML patients (25.6% vs 56.7% overall survival at 2 years; P = .032). Our results for the first time implicate BCOR in CN-AML pathogenesis.


Blood ◽  
2014 ◽  
Vol 123 (12) ◽  
pp. 1883-1886 ◽  
Author(s):  
Heiko Becker ◽  
Kenichi Yoshida ◽  
Nadja Blagitko-Dorfs ◽  
Rainer Claus ◽  
Milena Pantic ◽  
...  

Key Points The CBL syndrome may predispose to myeloid neoplasias other than juvenile myelomonocytic leukemia. Whole-exome sequencing identifies mutations that possibly cooperate with mutant CBL in AML development.


Blood ◽  
2019 ◽  
Vol 134 (Supplement_1) ◽  
pp. 5177-5177
Author(s):  
Chin-Hin NG ◽  
Alvin Yu-Jin Ng ◽  
Benedict Yan ◽  
Wee-Joo Chng

Background: Acute myeloid leukemia (AML) with double-mutated CEBPA (dmCEBPA) occurred in about 10% of AML and it is usually associated with normal karyotype AML. It is classified as a favorable risk AML with an estimated 5 years overall survival in excess of 50%. Patients who achieved complete remission (CR) with induction chemotherapy will be consolidated with chemotherapy. Around 40% of the patients would suffer a relapse and required further salvage chemotherapy followed by allogeneic stem cell transplant. Co-mutations occurred frequently in dmCEBPA AML with TET2 being the most commonly co-mutated (34%) followed by GATA1 mutation (21%), WT1(13.7%), DNMT3a (9.6%), ASXL1 (9.5%), NRAS (8.4%) and other less common genes. Only TET2 mutation appeared to have negative impact on prognosis. In this study, we explore the relapse cases with Whole-Exome sequencing (WES) and compared with a control case (Chemo-responsive dmCEBPA AML who is in continuous complete remission (CCR)). We aimed to identify novel mutations not previously reported and with potential as new prognostic marker as well as therapeutic target for further exploration. Method: We identified 3 relapsed dmCEBPA AML cases from our leukemia cell bank and compared with a case of chemo-responsive dmCEBPA AML who is still in CCR at 8 years follow-up. Duration of prior CR for case #1, #2 and #3 were 10 months, 1 year 9 month and 1 year 10 months. WES was performed for all 4 cases. In each case, the variants were annotated using the IonReporter software and an additional customized script that annotates for variant population frequency, genotype-phenotype associations and computational missense prediction tools. Variants were filtered by removing all reference calls, intergenic variants and variants not present in the chemoresponsive case. Only exonic and non-synonymous variants were considered. Next, we look for variants with a phenotype-genotype association common with the AML phenotype by looking for variants with "Leukemia" terms listed in OMIM. In addition, in order to identify novel mutations not presently associated with AML, we identified variants that had a "Pathogenic" entry in ClinVar. Results: All 4 cases revealed the typical CEBPA mutants with VAF exceeding 40% except one with germline mutation. When compared with the chemo-responsive case, KIT was mutated in 2 out of 3 relapse cases. WNT10A was mutated in all 3 cases. The details of the mutated genes are presented in Table 1 (see below). WNT10A gene encodes for a secretory signaling protein in the WNT family of structurally related genes that are involved WNT-beta-catenin-TCF signaling pathway. WNT10A is strongly expressed in cell lines of promyelocytic leukemia. Beta-catenin, the downstream target of the WNT signaling pathway, is highly expressed in poor prognostic AML cells (Staal et al. Nature review Immun 2008). The Gly213 residue is highly evolutionary conserved in vertebrate with a PhyloP score of 9.8. Both missense variants Gly213Ser and Arg171Cys are computationally predicted be damaging (DANN score 0.99). However, these 2 variants are fairly common in the East Asian population (gnomAD_EAS MAF G213S 2.7% & R171C 1.5%). Both variants are ACMG guidelines classified as Variants of Unknown Significance (VUS). KIT gene encodes for the proto-oncogene c-kit. Mutations in c-kit are associated with mastocytosis and AML. Both variants occur within the kinase domain (exon 17) of KIT. Asp816Val variant has been linked to poorer prognosis and worse outcome on AML patients. Both missense variants are computationally predicted to be damaging (DANN score 0.99). Both Asp816Val and Asn822Lys are AMCG classified as Likely Pathogenic and VUS respectively. Conclusion: With stringent criteria of filtering in WES of relapsed dmCEBPA cases, when compared with the control, we found that KIT was mutated in 2 out of 3 cases, while WNT10A was mutated in all 3 cases. Though the sample number was small, these findings would warrant further evaluation in larger cohort of dmCEBPA AML and interrogation in pre-clinical model. Table 1. Disclosures No relevant conflicts of interest to declare.


Sign in / Sign up

Export Citation Format

Share Document